A phase II trial of marimastat in advanced pancreatic cancer
Open accessThe DOI matches its Crossref record.
Abstract
Pancreatic cancer has a poor response to conventional chemotherapy and radiotherapy. Inhibition of matrix metalloproteinase activity involved in tumour invasion and metastases is a novel biological approach for cancer treatment. This multicentre phase II clinical trial assessed marimastat, an oral matrix metalloproteinase inhibitor, in patients with advanced pancreatic cancer. A total of 113 patients received marimastat for 28 days at 100 mg b.d. (n = 9), 25 mg o.d. (n = 90) or 10 mg b.d. (n = 14). Patients with a response to treatment could continue marimastat beyond 28 days. Of 113 patients, 90 (80%) completed the 28-day study and 83 (73%) continued treatment. The principal side effect was arthralgia in 14 (12%) patients at 28 days and 33 (29%) patients over the whole study. There were 31 patients (27%) who required dose modification. Of 76 patients with evaluable CA19-9 levels, 23 (30%) showed no increase or fall in CA19-9. Of 83 patients with radiologically assessable disease, 41 (49%) had stable disease. The median survival was 245 days for those with a stable or falling CA19-9 level 128 days in those with rising CA19-9. The overall survival was 3.8 months. 5.9 months for stage II, 4.7 months for stage III and 3 months for stage IV disease. Of 90 patients, 46 (51%) had stabilization or reduction in pain, mobility and analgesia scores. Further development and clinical evaluation of matrix metalloproteinase inhibitors for the treatment of pancreatic cancer is warranted. © 2001 Cancer Research Campaign http://www.bjcancer.com
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Because marimastat has previously progressed to clinical trials as a cancer treatment, its safety profile has already been determined, accelerating its development as a potential snakebite treatment (63, 64).”
From Assessing Target Specificity of the Small Molecule Inhibitor MARIMASTAT to Snake Venom Toxins: A Novel Application of Thermal Proteome Profiling (2024) · cites this paper as [63]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Metalloproteinase inhibitors: biological actions and therapeutic opportunities
Baker, A. H., Edwards, D. R., & Murphy, G. (2002) · Journal of Cell Science · doi:10.1242/jcs.00063 · Cited by 1,179
Development of Matrix Metalloproteinase Inhibitors in Cancer Therapy
Hidalgo, M., & Eckhardt, S. G. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.3.178 · Cited by 798
Bramhall, S. R., Schulz, J., Nemunaitis, J., Brown, P. D., Baillet, M., & Buckels, J. A. C. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600446 · Cited by 557
Self-citationLambert, E., Dassé, E., Haye, B., & Petitfrère, E. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2003.09.008 · Cited by 541
The role of matrix metalloproteinases (MMPs) in human caries
Chaussain-Miller, C., Fioretti, F., Goldberg, M., & Menashi, S. (2006) · Journal of Dental Research · doi:10.1177/154405910608500104 · Cited by 481
“Their performance and efficacy have been very limited in the setting of advanced metastatic cancer (Evans et al., 2001; Bramhall et al., 2002; Overall and Lopez-Otín, 2002) and were accompanied by unwanted side-effects, notably arthralgia and myalgia (Evans et al.”
BackgroundExploration of Global Gene Expression Patterns in Pancreatic Adenocarcinoma Using cDNA Microarrays
Iacobuzio-Donahue, C. A., Maitra, A., Olsen, M., Lowe, A. W., Van Heek, N. T., Rosty, C., Walter, K., Sato, N., Parker, A., Ashfaq, R., et al. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63911-9 · Cited by 473
Self-citationYeo, T. P., Hruban, R. H., Leach, S. D., Wilentz, R. E., Sohn, T. A., Kern, S. E., Iacobuzio-Donahue, C. A., Maitra, A., Goggins, M., Canto, M. I., et al. (2002) · Current Problems in Cancer · doi:10.1067/mcn.2002.129579 · Cited by 321
Senescent Carcinoma-Associated Fibroblasts Upregulate IL8 to Enhance Prometastatic Phenotypes
Wang, T., Notta, F., Navab, R., Joseph, J., Ibrahimov, E., Xu, J., Zhu, C.-Q., Borgida, A., Gallinger, S., & Tsao, M.-S. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0192 · Cited by 123
“Cell lines, tissue, and mouse strains This study was approved by the Research Ethics Board of the UniversityHealthNetwork (13-6377).”
MethodHall, S. R., Rasmussen, S. A., Crittenden, E., Dawson, C. A., Bartlett, K. E., Westhorpe, A. P., Albulescu, L.-O., Kool, J., Gutiérrez, J. M., & Casewell, N. R. (2023) · Nature Communications · doi:10.1038/s41467-023-43510-w · Cited by 63
“…action of these drugs being different, as marimastat directly inhibits metalloproteinases by acting as a peptidomimetic and binding covalently to the Zn 2+ ion present in the active site 31,45,78 – 80 , while the inhibitory mechanism of action of DMPS is solely the result of Zn 2+ chelation 32,78 .”
Thota, R., Maitra, A., & Berlin, J. D. (2017) · Pancreas · doi:10.1097/mpa.0000000000000753 · Cited by 12
Smith, C. F., Modahl, C. M., Ceja Galindo, D., Larson, K. Y., Maroney, S. P., Bahrabadi, L., Brandehoff, N. P., Perry, B. W., McCabe, M. C., Petras, D., et al. (2024) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2024.100779 · Cited by 11
Metadata
- Authors
- Evans, J. D., Stark, A., Johnson, C. D., Daniel, F., Carmichael, J., Buckels, J., Imrie, C. W., Brown, P., & Neoptolemos, J. P.
- Venue
- British Journal of Cancer
- Published
- 2001-12
- Volume
- 85
- Issue
- 12
- Pages
- 1865-1870
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2024605148
- Cited by
- 93
- References
- 0
- FWCI
- 3.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.